INTRODUCTION Non-eosinophilic esophagitis eosinophilic gastrointestinal disorders (non-EoE-EGIDs) have limited treatment options to induce histologic and clinical remission. Dupilumab is a human monoclonal antibody against the interleukin-4 receptor ɑ subunit, which has been reported to induce improvement in pediatric patients with non-EoE-EGIDs. METHODS We conducted a retrospective chart review to identify if patients with eosinophilic gastritis (EoG) and/or eosinophilic duodenitis (EoD) experience clinical and histologic remission with dupilumab. RESULTS Twelve patients were included (2 patients with EoG and EoD, 4 patients with EoG only, and 6 patients with EoD only). All patients experienced improvement of at least one symptom on dupilumab, 3 patients (25%) had no change in severity of one or more of their symptoms, and no patients had worsening symptoms. On dupilumab, 2 EoG patients (40%) and 3 EoD patients (33.3%) were completely asymptomatic. Histologic changes were investigated in a subanalysis including 8 patients (2 patients with EoG and EoD, 2 patients with EoG only, and 4 patients with EoD only). Median peak gastric eosinophil counts in EoG patients reduced from 80.5 eos/hpf (min-max 32-150, Q1-Q3 45.5-111) to 7.5 eos/hpf (min-max 0-28, Q1-Q3 1.5-16.8). Median peak duodenal eosinophil counts in EoD patients reduced from 39 eos/hpf (min-max 30-50, Q1-Q3 37.3-46.3) to 16.5 eos/hpf (min-max 30-50, Q1-Q3 37.3-46.3). All 4 patients (100%) with EoG, and 4 patients (66.6%) with EoD had histologic remission on dupilumab. DISCUSSION In this retrospective case series, we show preliminary evidence that dupilumab may be effective in inducing histologic and symptomatic remission in patients with non-EoE-EGIDs.

中文翻译：

---

Dupilumab 可诱导嗜酸性胃炎和十二指肠炎缓解：回顾性病例系列。

引言 非嗜酸性粒细胞性食管炎嗜酸性粒细胞性胃肠道疾病（非 EoE-EGID）诱导组织学和临床缓解的治疗选择有限。Dupilumab 是一种针对白细胞介素 4 受体 ɑ 亚基的人单克隆抗体，据报道可诱导非 EoE-EGID 儿科患者的病情改善。方法 我们进行了回顾性图表审查，以确定嗜酸性粒细胞性胃炎 (EoG) 和/或嗜酸性粒细胞性十二指肠炎 (EoD) 患者在使用 dupilumab 后是否出现临床和组织学缓解。结果 纳入 12 名患者（2 名患有 EoG 和 EoD 的患者，4 名仅患有 EoG 的患者，以及 6 名仅患有 EoD 的患者）。所有患者在 dupilumab 治疗后至少一种症状得到改善，3 名患者 (25%) 的一种或多种症状的严重程度没有变化，并且没有患者出现症状恶化。使用 dupilumab 后，2 名 EoG 患者 (40%) 和 3 名 EoD 患者 (33.3%) 完全无症状。在一项包括 8 名患者的亚分析中研究了组织学变化（2 名患者患有 EoG 和 EoD，2 名患者仅患有 EoG，4 名患者仅患有 EoD）。EoG 患者胃嗜酸性粒细胞计数峰值中位数从 80.5 eos/hpf（最小-最大 32-150，Q1-Q3 45.5-111）降低至 7.5 eos/hpf（最小-最大 0-28，Q1-Q3 1.5-16.8）。EoD 患者十二指肠嗜酸性粒细胞计数中位数峰值从 39 eos/hpf（最小-最大 30-50，Q1-Q3 37.3-46.3）减少至 16.5 eos/hpf（最小-最大 30-50，Q1-Q3 37.3-46.3）。所有 4 名 EoG 患者 (100%) 和 4 名 EoD 患者 (66.6%) 在 dupilumab 治疗后均获得组织学缓解。讨论 在这个回顾性病例系列中，我们显示了初步证据，表明 dupilumab 可能有效诱导非 EoE-EGID 患者的组织学和症状缓解。